Top

International Journal of Clinical Oncology

Published in:

01-06-2019 | Magnetic Resonance Imaging | Invited Review Article

Cryosurgery for primary breast cancers, its biological impact, and clinical outcomes

Authors: Masahiro Takada, Masakazu Toi

Published in: International Journal of Clinical Oncology | Issue 6/2019

Abstract

Recently, a number of new minimally invasive image-guided percutaneous ablation treatments, including cryoablation, radiofrequency ablation, microwave ablation, high-intensity focused ultrasound, laser ablation, and irreversible electroporation have been developed. Several studies have shown the feasibility and safety of these cryoablation therapies for the treatment of benign breast tumors and small invasive breast cancer. Although the complete response rate of cryoablation for breast cancer is reported to be relatively good, most studies enrolled a small number of patients, and so reliable conclusions could not be drawn. In this review, we introduce the mechanisms of action of cryoablation, and summarize the current literature on the efficacy and safety of cryoablation for breast cancer. Cryoablation also induces an immunomodulatory effect, which is an interesting topic of research in the era of immune checkpoint inhibitors. Cryoablation for primary tumor may enhance the treatment effect of immune checkpoint inhibitors in patients with breast cancer. Further investigations of this new therapeutic strategy are needed.

Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108. https://doi.org/10.3322/caac.21262 CrossRef

Fisher B, Jeong JH, Anderson S et al (2002) Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. New Engl J Med 347:567–575. https://doi.org/10.1056/NEJMoa020128 CrossRefPubMed

Fleming MM, Holbrook AI, Newell MS (2017) Update on image-guided percutaneous ablation of breast cancer. AJR Am J Roentgenol 208:267–274. https://doi.org/10.2214/AJR.16.17129 CrossRefPubMed

Chu KF, Dupuy DE (2014) Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer 14:199–208. https://doi.org/10.1038/nrc3672 CrossRefPubMed

Yang WL, Addona T, Nair DG et al (2003) Apoptosis induced by cryo-injury in human colorectal cancer cells is associated with mitochondrial dysfunction. Int J Cancer 103:360–369. https://doi.org/10.1002/ijc.10822 CrossRefPubMed

Alblin RJ, Soanes WA, Gonder MJ (1971) Prospects for cryo-immunotherapy in cases of metastasizing carcinoma of the prostate. Cryobiology 8:271–279CrossRefPubMed

Abdo J, Cornell DL, Mittal SK et al (2018) Immunotherapy plus cryotherapy: Potential augmented abscopal effect for advanced cancers. Front Oncol 8:85. https://doi.org/10.3389/fonc.2018.00085 CrossRefPubMedPubMedCentral

Kumar AV, Patterson SG, Plaza MJ (2019) Abscopal effect following cryoablation of breast cancer. J Vasc Interv Radiol 30:466–469. https://doi.org/10.1016/j.jvir.2018.12.004 CrossRefPubMed

Sabel MS, Kaufman CS, Whitworth P et al (2004) Cryoablation of early-stage breast cancer: work-in-progress report of a multi-institutional trial. Ann Surg Oncol 11:542–549. https://doi.org/10.1245/ASO.2004.08.003 CrossRefPubMed

10.

Simmons RM, Ballman KV, Cox C, ACOSOG Investigators et al (2016) A phase II trial exploring the success of cryoablation therapy in the treatment of invasive breast carcinoma: Results from ACOSOG (Alliance) Z1072. Ann Surg Oncol 23:2438–2445. https://doi.org/10.1245/s10434-016-5275-3 CrossRefPubMedPubMedCentral

11.

Mauri G, Sconfienza LM, Pescatori LC et al (2017) Technical success, technique efficacy and complications of minimally-invasive imaging-guided percutaneous ablation procedures of breast cancer: A systematic review and meta-analysis. Eur Radiol 27:3199–3210. https://doi.org/10.1007/s00330-016-4668-9 CrossRefPubMed

12.

Machida Y, Shimauchi A, Igarashi T, et al (2018) MRI findings after cryoablation of primary breast cancer without surgical resection. Acad Radiol. https://doi.org/10.1016/j.acra.2018.07.012(Epub ahead of print)CrossRefPubMed

13.

Pusceddu C, Melis L, Ballicu N et al (2017) Cryoablation of primary breast cancer in patients with metastatic disease: considerations arising from a single-centre data analysis. Biomed Res Int 2017:3839012. https://doi.org/10.1155/2017/3839012 CrossRefPubMedPubMedCentral

14.

Beji H, Pilleul F, Picard R et al (2018) Percutaneous cryoablation of breast tumours in patients with stable metastatic breast cancer: safety, feasibility and efficacy. Br J Radiol 91:20170500. https://doi.org/10.1259/bjr.20170500 CrossRefPubMedPubMedCentral

15.

Sabel MS, Nehs MA, Su G et al (2005) Immunologic response to cryoablation of breast cancer. Breast Cancer Res Treat 90:97–104. https://doi.org/10.1007/s10549-004-3289-1 CrossRef

16.

Liang S, Niu L, Xu K et al (2017) Tumor cryoablation in combination with natural killer cells therapy and herceptin in patients with HER2-overexpressing recurrent breast cancer. Mol Immunol 92:45–53. https://doi.org/10.1016/j.molimm.2017.10.003 CrossRefPubMed

17.

McArthur HL, Diab A, Page DB et al (2016) A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling. Clin Cancer Res 22:5729–5737. https://doi.org/10.1158/1078-0432.CCR-16-0190 CrossRefPubMedPubMedCentral

18.

Page DB, Yuan J, Redmond D et al (2016) Deep sequencing of T-cell receptor DNA as a biomarker of clonally expanded TILs in breast cancer after immunotherapy. Cancer Immunol Res 4:835–844. https://doi.org/10.1158/2326-6066.CIR-16-0013 CrossRefPubMedPubMedCentral

19.

Adams S, Loi S, Toppmeyer D, et al (2018) Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B of the Phase 2 KEYNOTE-086 study. Ann Oncol. https://doi.org/10.1093/annonc/mdy518 (Epub ahead of print)CrossRefPubMed

20.

Adams S, Schmid P, Rugo HS, et al (2018) Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the Phase 2 KEYNOTE-086 Study. Ann Oncol. https://doi.org/10.1093/annonc/mdy517 (Epub ahead of print)CrossRefPubMed

21.

Heery CR, O'Sullivan-Coyne G, Madan RA et al (2017) Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol 18:587–598. https://doi.org/10.1016/S1470-2045(17)30239-5 CrossRefPubMedPubMedCentral

22.

Nanda R, Chow LQ, Dees EC et al (2016) Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 Study. J Clin Oncol 34:2460–2467. https://doi.org/10.1200/JCO.2015.64.8931 CrossRefPubMed

23.

Rugo HS, Delord JP, Im SA et al (2018) Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. Clin Cancer Res 24:2804–2811. https://doi.org/10.1158/1078-0432.CCR-17-3452 CrossRefPubMed

24.

Schmid P, Adams S, Rugo HS, IMpassion130 Trial Investigators et al (2018) Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. New Engl J Med 379:2108–2121. https://doi.org/10.1056/NEJMoa1809615 CrossRefPubMed

25.

Morin J, Traore A, Dionne G et al (2004) Magnetic resonance-guided percutaneous cryosurgery of breast carcinoma: technique and early clinical results. Can J Surg 47(5):347–351PubMedPubMedCentral

26.

Pfleiderer SO, Marx C, Camara O et al (2005) Ultrasound-guided, percutaneous cryotherapy of small (%3c or = 15 mm) breast cancers. Invest Radiol 40(7):472–477CrossRefPubMed

27.

Pusztaszeri M, Vlastos G, Kinkel K et al (2007) Histopathological study of breast cancer and normal breast tissue after magnetic resonance-guided cryotherapy ablation. Cryobiology 55(1):44–51. https://doi.org/10.1016/j.cryobiol.2007.05.002 CrossRefPubMed

28.

Littrup PJ, Jallad B, Chandiwala-Mody P et al (2009) Cryotherapy for breast cancer: a feasibility study without excision. J Vasc Interv Radiol 20(10):1329–1341. https://doi.org/10.1016/j.jvir.2009.06.029 CrossRefPubMed

29.

Manenti G, Scarano AL, Pistolese CA, et al. (2013) Subclinical breast cancer: minimally invasive approaches. Our experience with percutaneous radiofrequency ablation vs. cryotherapy. Breast Care (Basel) 8(5):356–360. doi:10.1159/000355707

30.

Pusceddu C, Sotgia B, Amucano G et al (2014) Breast cryoablation in patients with bone metastatic breast cancer. J Vasc Interv Radiol 25(8):1225–1232. https://doi.org/10.1016/j.jvir.2014.05.001 CrossRefPubMed

31.

Gajda MR, Mireskandari M, Baltzer PA, et al. (2014) Breast pathology after cryotherapy. Histological regression of breast cancer after cryotherapy. Pol J Pathol 65(1):20–28CrossRefPubMed

32.

Cazzato RL, de Lara CT, Buy X et al (2015) Single-centre experience with percutaneous cryoablation of breast cancer in 23 consecutive non-surgical patients. Cardiovasc Intervent Radiol 38(5):1237–1243. https://doi.org/10.1007/s00270-015-1181-5 CrossRefPubMed

33.

Poplack SP, Levine GM, Henry L et al (2015) A pilot study of ultrasound-guided cryoablation of invasive ductal carcinomas up to 15 mm with MRI follow-up and subsequent surgical resection. AJR Am J Roentgenol 204(5):1100–1108. https://doi.org/10.2214/AJR.13.12325 CrossRefPubMedPubMedCentral

Title: Cryosurgery for primary breast cancers, its biological impact, and clinical outcomes
Authors: Masahiro Takada
Masakazu Toi
Publication date: 01-06-2019
Publisher: Springer Singapore
Keywords: Magnetic Resonance Imaging
Magnetic Resonance Imaging
Breast Cancer
Breast Cancer
Checkpoint Inhibitors
Published in: International Journal of Clinical Oncology / Issue 6/2019
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-019-01448-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2019

Efficacy and safety of oxaliplatin-based regimen versus cisplatin-based regimen in the treatment of gastric cancer: a meta-analysis of randomized controlled trials

Control of intracranial disease is associated with improved survival in patients with brain metastasis from hepatocellular carcinoma

Lymph node ratio has impact on relapse and outcome in patients with stage III melanoma

Diagnostic value of multimodal ultrasound imaging in differentiating benign and malignant TI-RADS category 4 nodules

RFA experiences, indications and clinical outcomes

Patterns of lymph node metastasis and the management of neck dissection for parotid carcinomas: a single-institute experience

Keynote webinar | Spotlight on antibody–drug conjugates in cancer